EXHIBIT 99.1
[ATS MEDICAL LOGO]
Contacts:
Michael Dale
President/CEO
763-553-7736
Investors:
EVC Group
Douglas Sherk, 415-896-6820
Jennifer Beugelmans, 646-277-8704
Media:
Steve DiMattia, 646-277-8706
FOR IMMEDIATE RELEASE
ATS MEDICAL REPORTS CONTINUED PROGRESS DURING THIRD QUARTER
Gross Margin Rises 7.1 Percentage Points Sequentially to 57.3%
Non-Mechanical Heart Valve Product Revenue Reaches 20%
Company Generates Positive Cash Flow from Operations
MINNEAPOLIS, Nov. 1, 2006 -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and
marketer of state-of-the-art cardiac surgery products and services, today
reported strong financial results for the third quarter ended September 30,
2006. Revenue for the quarter was $9.1 million, up 9.5% from $8.3 million
reported in the same quarter of 2005.
Revenue generated from products and services other than the Company's mechanical
heart valve increased 52.9% to $1.8 million and revenue from the Company's
mechanical heart valve product increased 2.1% as compared to the third quarter
of 2005. Revenues from products and services other than the Company's mechanical
heart valve represented 20.2% of total revenue compared with 16.4% in the second
quarter of 2006.
Gross margins for the third quarter of 2006 increased to 57.3% from 31.4% for
the third quarter of 2005 and 50.2% for the second quarter of 2006.
"Our strategy of providing state-of-the-art products and services to meet the
unique needs of the cardiac surgery market continues to evolve on all fronts,"
said Michael Dale, President and CEO. "In particular, our ongoing efforts to
improve the profitability and cash flow of our core business continue to yield
positive results. During the third quarter, our gross margins improved by more
than 25 percentage points compared with the third
quarter of last year. Also of note, our sales force continued to execute well on
our revenue diversification strategy, resulting in new product, non-mechanical
heart valve revenues growing to 20% of total sales. These important achievements
coupled with ongoing leverage of our balance sheet led us to a significant
milestone. We are pleased to report that we generated $221,000 in positive cash
flow from operations in the third quarter."
The operating loss for the period ended September 30, 2006 was $17.1 million
compared with an operating loss of $4.0 million in the third quarter of 2005.
The 2006 operating loss included an acquired in-process research and development
non-cash charge of $14.4 million resulting from the purchase of 3F Therapeutics
during the third quarter. Excluding this charge, the adjusted operating loss for
the third quarter was $2.7 million.
The net loss for the quarter was $17.3 million, or $0.55 per share compared with
the $4.1 million or $0.13 per share net loss in the third quarter of 2005.
Excluding the $14.4 million in-process research and development charge, the
third quarter 2006 adjusted net loss was $2.9 million or $0.09 per share, a 30%
decrease from the net loss for the third quarter of 2005.
During the first nine months ended September 30, 2006, revenue increased 20.3%
to $29.7 million from $24.7 million reported for the comparable period of 2005.
Gross margins for the nine-month period improved to 51.9% from 37.2% for the
same period of 2005. The operating loss was $21.9 million in the first nine
months of 2006 compared with $11.1 million in the comparable period of 2005.
Excluding the acquired in-process technology expense, adjusted operating loss
during the first nine months of 2006 would have been $7.5 million.
"While we enjoyed a positive third quarter performance, the highlight was the
completion of our acquisition of 3F Therapeutics," continued Mr. Dale. "Simply
said, 3F's tissue heart valve product pipeline is exciting. It's exciting for
our employees and even more exciting for our customers. From the business
perspective, 3F's technology expands our addressable market opportunity by
almost $700 million. What really makes 3F exciting for our Company and our
shareholders is the potential of this technology to gain significant market
share. 3F's patented tubular heart valve is novel in design and superior in
function. The 3F Enable(TM) and Entrata(TM) product platforms represent
pioneering approaches that may enable surgeons to expand less invasive heart
valve replacement to the general population. Lastly and very importantly, the
intellectual property underlying the 3F technology is supported by more than 130
issued and pending patents covering heart valve design, function, manufacturing
techniques and implantation methods for heart valves."
2006 OUTLOOK
"We continue to believe that for the full year we will
exceed $40 million in annual revenue. Our focus for the remainder of the year
will be the integration of 3F's business operations and new product planning.
Our focus in this regard will be 3F Therapeutics product development programs as
well as ATS development programs including the PARSUS(TM) blood filtration
technology and next-generation heart valve related research.
While we will generate a net loss for the year, we do believe we will
substantially improve the enterprise value of ATS Medical through the 3F
transaction as well as the continued execution of our strategy. Our 3F product
development milestones include initiation of the pivotal clinical study for the
Enable valve in the last half of the fourth quarter 2006 or early in the first
quarter of 2007 and the FDA approval of the ATS 3F(R) Aortic Bioprosthesis in
the second half of 2007. Additionally, we will formally launch the ATS 3F Aortic
Bioprosthesis in Europe in the first quarter of 2007," Mr. Dale concluded.
CONFERENCE CALL TODAY
ATS management will host a conference call and web cast today, November 1, 2006
at 5:00 p.m. ET to discuss its third quarter financial results, outlook for the
remainder of 2006 and current corporate developments. The dial-in number for the
conference call is 800-257-3401 for domestic participants and 303-205-0044 for
international participants.
A taped replay of the conference call will also be available beginning
approximately one hour after the call's conclusion and will remain available for
seven days. The replay can be accessed by dialing 800-405-2236 for domestic
callers and 303-590-3000 for international callers, using the passcode
11074143#. A live webcast of the call can be accessed at
http://www.atsmedical.com by clicking on the investors' icon. The replay of the
webcast will be available on the Company's website for one year.
DISCLOSURE OF NON-GAAP FINANCIAL MEASURES
ATS reports its financial results in accordance with generally accepted
accounting principles ("GAAP"). In addition, from time to time, we include other
measures in our releases which are not prepared in accordance with GAAP.
Investors should consider these non-GAAP measures in addition to, not as a
substitute for or as superior to, financial reporting measures prepared in
accordance with GAAP. In this release we have included adjusted versions of our
operating loss, net loss and net loss per share for the third quarter and first
nine months of 2006. These non-GAAP measures do not reflect the impact of a
$14.4 million an acquired in-process research and development charge incurred as
a result of the acquisition of 3F Therapeutics because we believe that this
charge will not be incurred on a regular basis. We use the adjusted operating
loss, adjusted net loss and adjusted net loss per share measures in our internal
analysis and review of our operational performance. We believe that these
non-GAAP measures provide investors with useful information in comparing our
performance over different periods, particularly when comparing one of these
periods to a period in which we did not incur this kind of charge. By using
these non-GAAP measures we believe investors get a better picture of the
performance of our underlying business. We have also included as an attachment
to this release a schedule which reconciles our operating loss, net loss and net
loss per share prepared in accordance with GAAP to our adjusted operating loss,
adjusted net loss and adjusted net loss per share presented above.
ABOUT ATS MEDICAL
ATS Medical, Inc. provides innovative products and services focused on cardiac
surgery. The company, global in scope, has been headquartered in Minneapolis,
Minnesota since its founding in 1991. More than 130,000 ATS Open Pivot(R) Heart
Valves, which utilize a unique pivot design resulting in exceptional performance
and low risk profile, have been implanted in patients worldwide. The ATS 3F(R)
brand encompasses multiple tissue heart valve product offerings at varying steps
from market introductions to clinical trials to development projects that
incorporate less invasive valve replacement technology. ATS Medical's focus on
serving the cardiac surgery community is further strengthened by offerings that
include ATS Simulus(TM) annuloplasty products for heart valve repair,
SurgiFrost(R) and FrostByte(TM) products for surgical cryoablation of cardiac
arrhythmias, RTI-Cardiovascular for allograft tissue services, and the
development of PARSUS blood filtration technology. The ATS Medical web site is
http://www.atsmedical.com.
SAFE HARBOR
This Press Release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the Company and
its management. Actual results could differ materially from those projected in
the forward looking statements as a result of a number of important factors,
including the results of clinical trials, the integration of 3F Therapeutics,
regulatory actions, competition, pricing pressures, supplier actions and
management of growth. For a discussion of these and other risks and
uncertainties that could affect the Company's activities and results, please
refer to the Company's filings with the Securities and Exchange Commission
including its Form 10-K for the year ended December 31, 2005, as amended, and
its Form S-4 Registration Statement, as amended, filed with respect to the
merger with 3F Therapeutics.
* * * *
ATS MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT PER SHARE AMOUNTS)
Three months ended Nine months ended
September 30, September 30,
---------------------- ----------------------
2006 2005 2006 2005
-------- -------- -------- --------
Net sales $ 9,122 $ 8,333 $ 29,709 $ 24,703
Cost of goods sold 3,894 5,714 14,302 15,489
-------- -------- -------- --------
Gross profit 5,228 2,619 15,407 9,214
Operating expenses:
Sales and marketing 5,287 4,323 15,233 13,765
Research and development 528 409 1,370 1,118
Acquired in-process research & development 14,400 -- 14,400 --
General and administrative 2,067 1,928 6,288 5,443
-------- -------- -------- --------
Total operating expenses 22,282 6,660 37,291 20,326
-------- -------- -------- --------
Operating loss (17,054) (4,041) (21,884) (11,112)
-------- -------- -------- --------
Interest expense, net (446) (37) (1,235) (58)
Change in value of derivative
liability bifurcated from
convertible senior notes 245 -- 1,525 --
-------- -------- -------- --------
Net loss ($17,255) ($ 4,078) ($21,594) ($11,170)
======== ======== ======== ========
Net loss per share:
Basic and diluted ($0.55) ($0.13) ($0.69) ($0.36)
Weighted average number of shares outstanding:
Basic and diluted 31,358 31,039 31,256 30,981
</Table>
ATS MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
September 30, December 31,
2006 2005
---------------- -----------------
ASSETS
Cash and short-term investments $16,343 $21,709
Accounts receivable 13,321 10,453
Inventories 19,269 21,286
Prepaid expenses 1,220 1,204
---------------- -----------------
Total current assets 50,153 54,652
Property and equipment, net 7,991 8,330
Intangible assets 33,807 22,015
Other assets 455 446
---------------- -----------------
TOTAL ASSETS $92,406 $85,443
================ =================
LIABILITIES & SHAREHOLDERS' EQUITY
Accounts payable $4,416 $3,598
Accrued compensation 2,462 2,394
Other accrued liabilities 2,493 1,410
Current maturities of long-term debt 1,133 833
---------------- -----------------
Total current liabilities 10,504 8,235
Convertible senior notes payable 17,364 18,776
Notes payable 1,478 903
Shareholders' equity 63,060 57,529
---------------- -----------------
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY $92,406 $85,443
================ =================
</Table>
ATS MEDICAL, INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW
(IN THOUSANDS)
Nine months ended
September 30,
----------------------
2006 2005
-------- ---------
OPERATING ACTIVITIES
Net loss ($21,594) ($11,170)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation 1,317 1,145
Loss on disposal of equipment 26 --
Stock compensation expense 794 359
Non-cash interest expense 350 22
Lower of cost or market adjustment -- 700
Change in value of convertible senior notes
derivative liability (1,525) --
Acquired in-process research & development 14,400 --
Changes in operating assets and liabilities 900 (742)
-------- --------
Net cash used in operating activities (5,332) (9,686)
INVESTING ACTIVITIES
Maturities of short-term investments, net of purchases 454 5,738
Payments for technology licenses (210) (1,817)
Acquisition costs, net of cash acquired (555) --
Net purchases of furniture, machinery and equipment (485) (1,507)
-------- --------
Net cash provided by (used in) investing activities (796) 2,414
FINANCING ACTIVITIES
Advances on notes payable 1,500 --
Repayments on notes payable (625) (556)
Net proceeds from sales of common stock 178 413
-------- --------
Net cash provided by (used in) financing activities 1,053 (143)
Other items 150 132
-------- --------
Decrease in cash and cash equivalents ($4,925) ($7,283)
======== ========
</Table>
ATS MEDICAL, INC.
RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES
(DOLLARS IN THOUSANDS)
UNAUDITED
<Table>
<Caption>
THREE-MONTHS NINE-MONTHS
ENDED ENDED
SEPTEMBER 30, SEPTEMBER 30,
2006 2006
------------- -------------
OPERATING LOSS, AS REPORTED $(17,054) $(21,884)
Adjustment to operating expenses:
Acquired in-process research & development 14,400 14,400
-------- --------
OPERATING LOSS, AS ADJUSTED $ (2,654) $ (7,484)
======== ========
NET LOSS, AS REPORTED $(17,255) $(21,594)
Adjustment to net loss:
Acquired in-process research & development 14,400 14,400
-------- --------
NET LOSS, AS ADJUSTED $ (2,855) $ (7,194)
======== ========
NET LOSS PER SHARE, AS REPORTED:
BASIC AND DILUTED $ (0.55) $ (0.69)
Adjustment to net loss per share:
Acquired in-process research & development 0.46 0.46
-------- --------
NET LOSS PER SHARE, AS ADJUSTED:
BASIC AND DILUTED $ (0.09) $ (0.23)
======== ========
Weighted average number of shares outstanding, basic
and diluted 31,358 31,256
</Table>
* * * *